Research programme: schizophrenia therapies - RocheAlternative Names: GlyT1 inhibitors - Roche; R1551
Latest Information Update: 15 Apr 2016
At a glance
- Originator Roche
- Class Small molecules
- Mechanism of Action Glycine transporter 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 15 Jan 2006 Preclinical trials in Schizophrenia in Switzerland (unspecified route)